Lilly paid $75 million upfront and committed up to $1.26 billion in total to license sonefpeglutide from Hanmi Pharm, securing rights to every market outside Korea for the Korean biotech’s phase 2 GLP-2 agonist.
The upfront’s roughly 6 cents on the dollar against total potential value, telling you how contingent the economics are on clinical execution. Hanmi retains Korea and stays in charge of finishing the ongoing phase 2 trial in short bowel syndrome; Lilly’s fresh studies start after that.
What does Lilly actually get? A monthly GLP-2 analog targeting SBS, a rare condition from loss of more than 60% of the small intestine that affects roughly 24.5 per 100,000 newborns globally. The only approved GLP-2 competitor is Takeda’s Gattex, a daily injection on the market since 2012. Sonefpeglutide’s monthly dosing is a real convenience upgrade in a population that often depends on parenteral nutrition.
The competitive picture thinned in December 2024, when Zealand Pharma’s glepaglutide got a complete response letter from FDA for insufficient efficacy evidence. That stumble leaves Gattex without a near-term challenger and clears the lane for whoever gets to market next.
Lilly’s buying spree this year already included in vivo CAR-T biotechs, vaccine companies, and JAK inhibitor Ajax Therapeutics, all funded by Zepbound revenues. Adding a GI asset extends the GLP franchise into the bowel, a logical adjacency to existing tirzepatide work in Crohn’s and ulcerative colitis. Can a phase 2 asset in a rare indication justify a $1.26 billion milestone ceiling? That’s the real math here.
— Diana Kowalski